MATINAS BIOPHARMA HOLDINGS, INC. Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross of $811.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross · last filed 2023-03-15
- MATINAS BIOPHARMA HOLDINGS, INC. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2022 was $811.00K, a 62.78% decline from fiscal 2021.
- MATINAS BIOPHARMA HOLDINGS, INC. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2021 was $2.18M.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 12 month |
|---|---|
| 2022-12-31 | $811.00K 10-K · filed 2023-03-15 |
| 2021-12-31 | $2.18M 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |